EGFR and non-small cell lung carcinoma: A trial of 40–80 mg/day osimertinib plus 150–325 mg/day navitoclax was conducted in 27 patients with EGFR-mutated NSCLC (including those with T790M-positive tumors) previously treated with EGFR-TKIs.